Neil Cross
| Doctor Neil Cross BSc, PgCert LTHE, FHEA, PhD | |
|---|---|
| Born | 1974 (age 51–52) United Kingdom |
| 🏳️ Nationality | British |
| 💼 Occupation | |
| Known for | 3D cell culture models apoptotic research gold nanoparticle radiosensitisation |
| 🏅 Awards | Fellow of Advance HE (FHEA) |
| 🌐 Website | Official profile[1] |
Neil Cross (born 1974) is a British cancer biologist and academic.
Cross completed a BSc in Biomedical Chemistry at Sheffield Hallam University in 1996 and a PhD at the University of Sheffield in 2002 under Professor Ian Rennie and Dr Karen Sisley. From 1996 to 2008, he worked at the University of Sheffield as a research fellow.[2]
In 2008, Cross joined Sheffield Hallam University as a Senior Lecturer in molecular and cell biology. He was promoted to Reader in cancer biology in 2017, and to Associate Professor in 2024, recognising his contributions to research, teaching, and academic leadership. He currently serves as Course Leader for the BSc (Hons) Biomedicine and Health Science programme at Sheffield Hallam.[2] As of 2025, Cross has authored 96 peer-reviewed journal articles, with his work cited more than 2,600 times.[3]
Cross's research spans three main areas:
- 3D cell culture models: Developing spheroid models that replicate tumour microenvironments—such as hypoxia, nutrient gradients, and limited drug penetration—for testing cancer therapies. This work is supported by NC3Rs, Innovate UK, Cancer Research UK, and the Marie Skłodowska-Curie Doctoral Training Alliance programme.[4]
- Programmed cell death: Investigating resistance mechanisms to TRAIL (tumour necrosis factor‑related apoptosis‑inducing ligand), and exploring how agents such as HDAC inhibitors, nuclear export inhibitors, and proteasome inhibitors can restore cell death pathways. Research also includes studies on ferroptosis in breast cancer spheroid models.[5]
- Gold nanoparticle radiosensitisation: Employing phosphonium‑conjugated gold nanoparticles to target mitochondria and the nucleus—enhancing photothermal and radiotherapy responses in tumour cells—conducted in collaboration with Professor Neil Bricklebank.[6]
References
- ↑ "Neil Cross | Sheffield Hallam University".
- ↑ 2.0 2.1 "Neil Cross | Sheffield Hallam University". www.shu.ac.uk. Retrieved 2025-06-17.
- ↑ "Google Scholar". scholar.google.co.uk. Retrieved 2025-06-17.
- ↑ Flint, Lucy E.; Hamm, Gregory; Ready, Joseph D.; Ling, Stephanie; Duckett, Catherine J.; Cross, Neil A.; Cole, Laura M.; Smith, David P.; Goodwin, Richard J. A.; Clench, Malcolm R. (2020-09-15). "Characterization of an Aggregated Three-Dimensional Cell Culture Model by Multimodal Mass Spectrometry Imaging". Analytical Chemistry. 92 (18): 12538–12547. doi:10.1021/acs.analchem.0c02389. ISSN 0003-2700. PMC 7497704 Check
|pmc=value (help). PMID 32786495 Check|pmid=value (help). - ↑ Hudson, Katie; Cross, Neil; Jordan-Mahy, Nicola; Leyland, Rebecca (2020-10-21). "The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment". Frontiers in Immunology. 11. doi:10.3389/fimmu.2020.568931. ISSN 1664-3224. PMC 7609400 Check
|pmc=value (help). PMID 33193345 Check|pmid=value (help). - ↑ Lalwani, Nikhil; Chen, Yu-Su; Brooke, Gemma; Cross, Neil A.; Allen, David W.; Reynolds, Alan; Ojeda, Jesús; Tizzard, Graham J.; Coles, Simon J.; Bricklebank, Neil (2015-02-19). "Triphenylarsonium-functionalised gold nanoparticles: potential nanocarriers for intracellular therapeutics". Chemical Communications. 51 (19): 4109–4111. doi:10.1039/C4CC09304F. ISSN 1364-548X. PMID 25670649.
This article "Neil Cross (Academic)" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Neil Cross (Academic). Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
